SMALL MOLECULE PREFILLED SYRINGES MARKET ANALYSIS

Global small molecule prefilled syringes market is estimated to be valued at US$ 18.98 Bn  in 2023, and is expected to exhibit a CAGR of 5.2% during the forecast period (2023-2030).

Analysts’ Views on Global Small Molecule Prefilled Syringes Market:

A pre-filled syringe is a disposable syringe that is already filled with the substance to be injected. The prefilled syringe that already contains the injection liquid. A prefilled syringe is a single dose of medication with a needle attached by the manufacturer. Increasing new product launch by market players, increasing number of chronic diseases, adoption of self injection devices are expected to create lucrative growth opportunities in the market.

Figure 1. Global Small Molecule Prefilled Syringes Market Share (%), By Type, 2023

To learn more about this report, request a free sample copy

Global Small Molecule Prefilled Syringes Market– Drivers

• Increasing incidence of chronic diseases: Increasing prevalence of chronic diseases is expected to drive growth of global small molecule prefilled syringes market. For instance, in June 2021, according to the fact sheet published by World Health Organization (WHO), , in 2019, an estimated 17.9 Mn people died from cardiovascular disease, accounted 32% of all global deaths. Among which, 85% of these deaths were due to heart attacks and strokes. Heart disease is the main cause of death in the U.S,for men, women, and people of most racial and ethnic groups. In theU.S., one person dies from cardiovascular disease every 33 seconds. In 2021, over 695,000 people in the U.S.died from heart disease thataccounted for one out of every five deaths.
• Increasing product launch by market players: The main benefits of prefilled syringes over conventional drug delivery systems are the improved product safety, self-administration, accurate dosing, and low chances of drug contamination. Self-injection advantage of prefilled syringes is a major factor that boosts adoption of the prefilled syringes, thus, drives growth of the global small molecule prefilled syringe market. For instance, in July 2022, Fresenius Kabi AG, a global healthcare company, expanded its simplist ready-to-administer prefilled syringe portfolio by launching adenosine injection in prefilled syringes that is indicated for the treatment of tachycardia.

Figure 2. Global Small Molecule Prefilled Syringes Market Share(%), By Region, 2023

To learn more about this report, request a free sample copy

Global Small Molecule Prefilled Syringes Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global small molecule prefilled syringes market over the forecast period. North America is estimated to hold 33.5 % of the market share in 2023. North America small molecule prefilled syringes market is expected to witness significant growth in thenear future due toincreasing product approvals by the regulatory authorities. For instance, in February 2022, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced that it had received approval by the U.S. Food and Drug Administration (FDA) for its single-dose prefilled injection syringe (PFS) named TAKHZYRO (lanadelumab-flyo) for the prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients of age 12 years and older. The PFS is ready-to-use and requires fewer preparation steps than the current TAKHZYRO vial injection, while reducing supplies and waste.

Global Small Molecule Prefilled Syringes Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore faced problemsproblems regardingtransportation and distribution of healthcare products.

In 2020, the COVID-19 pandemic disrupted health-care delivery around the world including delay in needle or syringe related diagnosis and treatment. Therefore, the impact of COVID-19 is expected to hamper growth of global small molecule prefilled syringes market. For instance, in September 2020, according to an article published by International Journal of Drug Policy, the needle and syringe programs (NSPs) are organized for population for free access to injectables and for awareness of the adverse effects associated with injecting drugs. According to the same source, the restrictions due to the pandemic resulted in a 36% decrease in the number of needle and service programs (NSP) clients in England, a 36% decrease in visits, and a 29% decrease in needle distribution as compared to 2019. NSP coverage for those injecting psychoactive drugs was cut in half, falling from 14 needles per week on March 15, 2020, to seven needles per week by mid-April 2020. 

Global Small Molecule Prefilled Syringes Market Segmentation:

Global small molecule prefilled syringes market  is segmented into type, material  type,  application,  distribution channel, and  region.

• By type, the market is segmented into single-chamber prefilled syringes, dual-chamber prefilled syringes, and customized prefilled syringes. Out of which, the single-chamber prefilled syringes segment is expected to hold a dominant position in the global small molecule prefilled syringes market during the forecast period due to product advancements by market players.
• By material type, the market is segmented into glass and plastic & polymer. Out of which, the plastic & poylmer segment is expected to hold a dominant position in the global small molecule prefilled syringes market during the forecast period due to its a high-performance thermoplastic with high chemical inertness, good barrier properties and a low extraction and leachability profile; Therefore, it is suitable for pre-filled syringes for intravenous medications used in hospitals.
• By application, the market is segmented into diabetes, cancer, opthalmology, anaphylaxis, rheumatoid arthritis, and others (thrombosis, etc.). Out of which, diabetes segment is expected to dominate the market over the forecast period due to increasing prevalence of diabetes in adult population.
• By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospitals pharmacies segment is expected to dominate the market over the forecast period due to ease of use.
• Among all the segmentation, the application segment is expected to dominate the market over the forecast period due to increasing prevalence of diseases such as diabetes and others.

Global Small Molecule Prefilled Syringes Market- Cross Sectional Analysis

Key players operating in the global small molecule prefilled syringes market are using  advanced technology in emerging economies, and this is expected to drive  small molecule prefilled syringes market in Asia Pacific region. For instance, in March 2020, Xeris Pharmaceuticals, Inc., a pharmaceutical company, announced that it is developing of using theirnovel formulation technology platforms to develop and commercialize ready-to-use injectable and infusion drug formulations emphasizes the importance of Gvoke PFS for people with diabetes and encourages healthcare professionals to talk to their at-risk patients about the availability of glucagon.

Global Small Molecule Prefilled Syringes Market: Key Developments

• In June 2022, Elektrofi, a biopharmaceutical company, announced that it had secured funding to support the advancement of candidates based on itsdrug delivery technology into the clinic. By signing deals with companies like Argenx, immunology company and Takeda Pharmaceutical, a pharmaceutical company, had raised US$40 Mn to build a GMP production line and double the workforce.
• In September 2021, Lonza, a global pharmaceutical company, announced its plan to invest in additional production capacity for pharmaceuticals in Switzerland. This investment will finance an additional aseptic flexible filling line for clinical drug supply in Stein (CH). The new line supports the filling and processing of liquid and lyophilized bottles as well as cartridges and prefilled syringes. The new filling line will enable Lonza to process various modalities for its customers including monoclonal antibodies, bioconjugates, viral vectors and other gene therapy products.
• In May 2020, the U.S. Department of Health and Human Services announced a US$ 138 Mncontract with ApiJect Systems America for “Project Jumpstart” and “RAPID USA,” which together will significantly expand manufacturing capacity for domestically manufactured medical injection devices in the U.S which has begun in October 2020.

Global Small Molecule Prefilled Syringes Market: Key Trends

Introduction of small molecule prefilled syringes with advanced technology: Introduction of small molecule prefilled Ssyringes with advanced technology in the market is expected to drive growth of the global small molecule prefilled syringes market over the forecast period. For instance, in September 2022, BD, a global medical technology company, introduced a next-generation prefillable glass syringe (PFS) that sets a new performance standard for vaccine PFS with new and tightened processability specifications : cosmetics, contaminants and integrity.

Global Small Molecule Prefilled Syringes Market: Restraint

• Product recall: The regulatory authorities are recalling some prefilled syringes due to increase in their adverse effects such as causing embolism in the body, and this is expected to hinder growth of global small molecule prefilled syringes market over the forecast period. For instance, in August 2021, the U.S. Food and Drug Administration identified monoject flush prefilled syringes (0.9% sodium chloride) as a Class I recall, and the most serious type of recall and use of these devices may cause serious injuries or even death. Monoject flush prefilled syringes was marketed by Cardinal Health, a U.S. -based multinational health care services company.
• Counterbalances: To overcome the challenges faced due to product recall, the manufacturing companies are expected to upgrade or standardize the production processes of the prefilled syringes to ensure safety and security for the patients.

Global Small Molecule Prefilled Syringes Market - Key Players

Major players operating in the global small molecule prefilled syringes market include BD, Cytiva, Merck KGaA, Gaplast, Ascendia Pharmaceuticals, Sanofi, Viatris Inc. (Mylan N.V.), Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Fresenius Kabi AG and McKesson Corporation.

Definition: A prefilled syringe (PFS) is a needle-based injection method that has been pre-filled with the substance that will be delivered. For drug containment and delivery, many autoinjectors rely on a prefilled glass syringe. This prefilled syringe is made up of several components that must be verified using a range of standard tests in order to establish the integrity and operation of the syringe system and, ultimately, ensure proper drug containment and expulsion and the highest level of comfort for the patient.